Surveillance of patients with cirrhosis remains suboptimal in the United States
Regular monitoring/surveillance for liver complications is crucial in the management of patients with cirrhosis to reduce morbidity and mortality. Recommendations from professional societies are available but adherence is not well studied, especially outside of academic centers. We aimed to determine the frequencies and factors associated with laboratory monitoring, hepatocellular carcinoma (HCC) and esophageal varices (EV) surveillance in patients with cirrhosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - May 6, 2021 Category: Gastroenterology Authors: Yee Hui Yeo, Jungyun Hwang, Donghak Jeong, Nolan Dang, Leslie Y. Kam, Linda Henry, Haesuk Park, Ramsey Cheung, Mindie H. Nguyen Source Type: research

Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease
Nonalcoholic Fatty Liver Disease (NAFLD), the hepatic correlate of the metabolic syndrome, is a major risk factor for hepatobiliary cancer (HBC). Although chronic inflammation is thought to be the root cause of all these diseases, the mechanism whereby it promotes HBC in NAFLD remains poorly understood. Here we aim to evaluate the hypothesis that inflammation-related dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes HB carcinogenesis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - May 5, 2021 Category: Gastroenterology Authors: Jeongeun Hyun, Muthana Al Abo, Rajesh Kumar Dutta, Seh Hoon Oh, Kun Xiang, Xiyou Zhou, Raquel Maeso-D íaz, Rebecca Caffrey, Arun J. Sanyal, Jennifer A. Freedman, Steven R. Patierno, Cynthia A. Moylan, Manal F. Abdelmalek, Anna Mae Diehl Source Type: research

Comment to the letter of Bril F et al. “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?”
we read with great interest the article: “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?” by Bril F. et al. recently published in J Hepatol1. In our opinion, several considerations arise leading to stress further the possibility that the described association is indeed coincide ntal, as also acknowledged by the authors. (Source: Journal of Hepatology)
Source: Journal of Hepatology - May 5, 2021 Category: Gastroenterology Authors: Pier Leopoldo Capecchi, Pietro Enea Lazzerini, Stefano Brillanti Tags: Letter to the Editor Source Type: research

Understanding HBcrAg components helps the better interpretation of clinical HBcrAg assay results
We read the paper with great interest from Inoue et al. on the development of a novel high-sensitivity hepatitis B core-related antigen assay (iTACT-HBcrAg) and its application for monitoring hepatitis B e antigen (HBeAg)-negative patients and HBV reactivation (1). Without a doubt, this high-sensitivity HBcrAg assay improves the sensitivity of the current HBcrAg assay and is timely for the ongoing pursuit for a HBV cure. However, a few important issues need to be clarified. (Source: Journal of Hepatology)
Source: Journal of Hepatology - May 5, 2021 Category: Gastroenterology Authors: Xupeng Hong, Jianming Hu Tags: Letter to the Editor Source Type: research

Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990 –2019
Acute viral hepatitis (AVH) represents an important global health problem; however, the progress in understanding AVH is limited because of the priority of combating persistent hepatitis B (HBV) and C (HCV) virus infections. Therefore, an improved understanding of the burden of AVH is required to help design strategies for global intervention. (Source: Journal of Hepatology)
Source: Journal of Hepatology - May 4, 2021 Category: Gastroenterology Authors: Dan-Yi Zeng, Jing-Mao Li, Su Lin, Xuan Dong, Jia You, Qing-Qing Xing, Yan-Dan Ren, Wei-Ming Chen, Yan-Yan Cai, Kuangnan Fang, Mei-Zhu Hong, Yueyong Zhu, Jin-Shui Pan Source Type: research

Resolution of hepatitis E virus infection in CD8+ T cell depleted rhesus macaques
HEV is a significant cause of acute hepatitis globally. Some genotypes establish persistent infection when immunity is impaired. Adaptive immune mechanisms that mediate resolution of infection have not been identified. Here, the requirement for CD8+ T cells to control HEV infection was assessed in rhesus macaques, a model of acute and persistent HEV infection in humans. (Source: Journal of Hepatology)
Source: Journal of Hepatology - May 4, 2021 Category: Gastroenterology Authors: William Bremer, Heather Blasczyk, Xin Yin, Eduardo Salinas Duron, Arash Grakoui, Zongdi Feng, Christopher Walker Source Type: research

Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression
A holistic insight on the relationship between obesity and metabolic dysfunction-associated fatty liver disease is an unmet clinical need. Omics investigations can be used to investigate the multifaceted role of altered mitochondrial pathways to promote nonalcoholic steatohepatitis, a major risk factor for liver disease-associated death. There are no specific treatments but remission via surgery might offer an opportunity to examine the signaling processes that govern the complex spectrum of chronic liver diseases observed in extreme obesity. (Source: Journal of Hepatology)
Source: Journal of Hepatology - May 4, 2021 Category: Gastroenterology Authors: Noem í Cabré, Fedra Luciano-Mateo, Douglas J. Chapski, Gerard Baiges-Gaya, Salvador Fernández-Arroyo, Anna Hernández-Aguilera, Helena Castañé, Elisabet Rodríguez-Tomàs, Marta París, Fàtima Sabench, Daniel Del Castillo, Josep M. del Bas, Mercedes Source Type: research

The times they are a-changing – A refined proposal for finite HBV nucleos(t)ide analog therapy
Although discontinuation of nucleos(t)ide analogue (NA) treatment before HBsAg loss is part of all current hepatitis B virus (HBV) treatment guidelines for HBeAg-positive patients who achieved HBeAg seroconversion, a treatment endpoint known to be associated with silencing of HBV transcriptional activity and restoration of HBV-specific immune control, it is still highly controversial whether it is even appropriate to consider NA discontinuation before HBsAg loss in the HBeAg-negative phase. Despite the growing evidence that a relevant, albeit small, proportion of patients with HBeAg-negative disease can be cured by stoppin...
Source: Journal of Hepatology - May 3, 2021 Category: Gastroenterology Authors: Thomas Berg, Pietro Lampertico Tags: Expert Opinion Source Type: research

Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS).
Liver transplantation (LT) has been proposed to be an effective salvage therapy even for the sickest patients with acute-on-chronic liver failure (ACLF). This large collaborative study was designed to address the current clinical practice and outcomes of ACLF patients wait listed (WL) for LT in Europe. (Source: Journal of Hepatology)
Source: Journal of Hepatology - May 2, 2021 Category: Gastroenterology Authors: Luca S. Belli, Christophe Duvoux, Thierry Artzner, William Bernal, Sara Conti, Paolo A. Cortesi, Sophie-Caroline Sacleux, George-Philippe Pageaux, Sylvie Radenne, Jonel Trebicka, Javier Fernandez, Giovanni Perricone, Salvatore Piano, Silvio Nadalin, Maria Source Type: research

Acute severe autoimmune hepatitis – timing for steroids and role of other immunosuppressive agents
We read with great interest the manuscript by de Martin et al.,1 reporting early predictive factors for a non-response to corticosteroid therapy in acute severe autoimmune hepatitis (AIH). The authors propose a score to help identify patients who do not respond to corticosteroids and may require urgent liver transplantation (LT). (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 29, 2021 Category: Gastroenterology Authors: Rodrigo Liberal, Guilherme Macedo Tags: Letter to the Editor Source Type: research

Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
We read with interest the article by Alvarado-Tapias et al.1 which provides valuable information about the impact of non-selective beta blockers (NSBB) on hemodynamics in patients with decompensated cirrhosis. The study eloquently showed that patients with decompensated cirrhosis and greater decline in cardiac output (CO) while on NSBB (CO (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 28, 2021 Category: Gastroenterology Authors: Manhal Izzy, Grace Lin, Kymberly D. Watt Tags: Letter to the Editor Source Type: research

Current knowledge and management of portal vein thrombosis in cirrhosis
Portal vein thrombosis (PVT) is a complication of cirrhosis that is being increasingly recognized and increases in parallel with the severity of cirrhosis. Several risk factors have been associated with the occurrence and progression of PVT. Although the negative effect of complete PVT on the surgical outcome of liver transplant recipient is clear, its impact on cirrhosis progression remains uncertain. Treatment options include anticoagulants and interventional thrombolytic therapies, which are chosen almost on a case-by-case basis depending on patient and thrombus characteristics. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 27, 2021 Category: Gastroenterology Authors: Marco Senzolo, Guadalupe Garcia-Tsao, Juan Carlos Garc ía-Pagán Tags: Review Source Type: research

External validation of the freiburg index of post-TIPS survival
We read with great interest the article “Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival” by Bettinger et al..1 We congratulate the authors on developing a novel model (the FIPS score) to predict 3- and 6-month survival after planned TIPS implantation using four easily obtainable prognost ic factors: age, creatinine, bilirubin, and albumin. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 26, 2021 Category: Gastroenterology Authors: Frederik Kraglund, Rasmus Hvidbjerg Gantzel, Peter Jepsen, Niels Kristian Aagaard Tags: Letter to the Editor Source Type: research

Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
We thank Dr. Stockhoff and her team for their interest in our study1 and their analyses that confirmed and even expanded the prognostic impact of the FIPS score to patients with decompensated liver cirrhosis without TIPS implantation.2 With great interest, we recognize their efforts in addressing some important remaining questions of our study especially with respect to the clinical application of the FIPS score for allocation to TIPS implantation. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 25, 2021 Category: Gastroenterology Authors: Dominik Bettinger, Roman Kloeckner, Tobias Boettler, Robert Thimme, Michael Schultheiss Tags: Letter to the Editor Source Type: research

Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis
This study aimed to assess whether BIs influence the risk of decompensation and survival in patients with compensated cirrhosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 24, 2021 Category: Gastroenterology Authors: C àndid Villanueva, Agustín Albillos, Joan Genescà, Joan C. Garcia-Pagan, Anna Brujats, José L. Calleja, Carles Aracil, Rafael Bañares, Rosa M. Morillas, María Poca, Beatriz Peñas, Salvador Augustin, Juan G. Abraldes, Edilmar Alvarado, Ferran Torre Source Type: research

Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study
Coronavirus disease 2019 (COVID-19) has caused a devastating global pandemic since early 2020.1,2 We read with interest the recent article by Cornberg et al.,1 in which they summarized the data on vaccine safety, immunogenicity, and efficacy in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has progressed at an unprecedented rate with encouraging safety and efficacy data emerging from clinical trials. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 24, 2021 Category: Gastroenterology Authors: Jitao Wang, Zhiyun Hou, Jianxin Liu, Ye Gu, Yunhong Wu, Zhenhuai Chen, Jiansong Ji, Shiqi Diao, Yuanwang Qiu, Shengqiang Zou, Aiguo Zhang, Nina Zhang, Fengxian Wang, Xue Li, Yan Wang, Xing Liu, Cheng Lv, Shubo Chen, Dengxiang Liu, Xiaolin Ji, Chao Liu, Ta Tags: Letter to the Editor Source Type: research

Letter regarding “association of liver abnormalities with in-hospital mortality in patients with COVID-19”
With great enthusiasm, we read a breakthrough study demonstrating the association of liver abnormalities with in-hospital mortality in patients with COVID-19.1 Integrating with 10 candidate predictor parameters determined by multivariate regression analyses, Ding Z and colleagues formulated a novel prognostic nomogram to predict the survival of patients with COVID-19. However, several crucial pitfalls may as well be taken into account. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 24, 2021 Category: Gastroenterology Authors: Meng-Si Luo, Guan-Jiang Huang Tags: Letter to the Editor Source Type: research

Risk stratification in hospitalized COVID-19 patients
Ding et al. recently published a retrospective analysis of potential predictors for mortality of 2073 hospitalized Chinese COVID-19 patients.1 As their main findings, they reported that increased liver parameters as well as liver injury were predictive for 28-day mortality, and proposed a nomogram that estimates the mortality risk of hospitalized patients with COVID-19 disease. However, as the understanding of COVID-19 disease improves, it becomes evident that the disease may present differently in different regions. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 23, 2021 Category: Gastroenterology Authors: Angela Horvath, Theresa Lind, Natalie Frece, Herbert Wurzer, Vanessa Stadlbauer Tags: Letter to the Editor Source Type: research

Robert W Schrier, an influential observer from outside Hepatology (1936 –2021)
Robert William Schrier, one of the greatest nephrologists of all time, died on January 23, 2021. He is survived by his beloved wife Barbara, his five children and a number of grandchildren. It is not common that a top specialty journal publishes an obituary about a physician from another specialty, unless he/she has made exceptional contributions to the field. This is the case of Robert W Schrier whose vision from the Nephrology field provided important clues to unveil some very relevant pathophysiological “mysteries” of Hepatology, on the formation of ascites and edema and the development of kidney abnormaliti...
Source: Journal of Hepatology - April 21, 2021 Category: Gastroenterology Authors: Pere Gin ès Tags: Obituary Source Type: research

A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy
Golexanolone is a novel small molecule GABA-A receptor modulating steroid antagonist under development for treatment of cognitive and vigilance disorders due to allosteric over-activation of GABA-A receptors by neurosteroids. It restored spatial learning and motor coordination in animal models of hepatic encephalopathy (HE) and mitigated the effects of intravenous allopregnanolone in healthy adults in a dose-dependent fashion. Here we report golexanolone safety, pharmacokinetics (PK) and effects on the electroencephalogram (EEG), subjective sleepiness and cognitive performance in adult patients with cirrhosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 20, 2021 Category: Gastroenterology Authors: Sara Montagnese, Mette Lauridsen, Hendrik Vilstrup, Lisa Zarantonello, Geza Lakner, Sergey Fitilev, Igor Zupanets, Irina Kozlova, Elena Bunkova, Krzysztof Tomasiewicz, Jan Erik Berglund, Fredrik Rorsman, Hannes Hagstr öm, Stergios Kechagias, Carin Edmark Source Type: research

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients
Two SARS-CoV-2 mRNA vaccines were approved to prevent COVID-19 infection, with reported vaccine efficacy of 95%. Liver transplant (LT) recipients are at risk for lower vaccine immunogenicity and were not included in the registration trials. We assessed vaccine immunogenicity and safety in this special population. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 20, 2021 Category: Gastroenterology Authors: Liane Rabinowich, Ayelet Grupper, Roni Baruch, Merav Ben-Yehoyada, Tami Halperin, Dan Turner, Eugene Katchman, Sharon Levi, Inbal Houri, Nir Lubezky, Oren Shibolet, Helena Katchman Source Type: research

Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) poses an impending clinical burden. Genome-wide association studies have revealed a limited contribution of genomic variants to the disease, requiring alternative but robust approaches to identify disease-associated variants and genes. We carried out a disease-specific expression quantitative trait loci (eQTL) screen to identify novel genetic factors that specifically act on NAFLD progression on the basis of genotype. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 20, 2021 Category: Gastroenterology Authors: Taekyeong Yoo, Sae Kyung Joo, Hyo Jung Kim, Hyun Young Kim, Hyungtai Sim, Jieun Lee, Hee-Hoon Kim, Sunhee Jung, Youngha Lee, Oveis Jamialahmadi, Stefano Romeo, Won-Il Jeong, Geum-Sook Hwang, Keon Wook Kang, Jae Woo Kim, Won Kim, Murim Choi, Innovative Tar Source Type: research

Do we need to re-define the baveno VI elastography criteria for compensataed advanced chronic liver disease (cACLD)? Letter to the editor in relation to “refining the baveno VI elastography criteria for the definition of compensated advanced chronic liver disease” by papatheodoridi et al.
We read with interest the article by Papatheodoridi et al.1 proposing a change in the cut-offs for excluding and diagnosing compensated advanced chronic liver disease (cACLD). We share with the authors the need for validation of these criteria for ruling in and out cACLD. However, we have concerns with the proposed changes and the clinical implications they carry. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 20, 2021 Category: Gastroenterology Authors: Joan Genesc à, Juan G. Abraldes, Jaime Bosch Tags: Letter to the Editor Source Type: research

Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience
Non-Alcoholic Fatty Liver Disease (NAFLD) is defined as an excess hepatic fat accumulation after the exclusion of heavy alcohol use or other secondary causes of steatosis. In 2018, it was estimated that NAFLD affects about the 25% of the world population, with the highest prevalence in South America (32%).1 Worryingly, it has been estimated that liver deaths related to NAFLD will increase by 178% by 2030,1 with no approved drug treatment to date. Thus, NALFD represents a burden to health and economic systems in all societies. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 20, 2021 Category: Gastroenterology Authors: Nahum Mendez-Sanchez, Luis Diaz-Orozco, Jacqueline Cordova-Gallardo Tags: Letter to the Editor Source Type: research

Reply to “Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings”
We thank Dr. Martin and colleagues for their interest in our study and for presenting additional data on the usage of glecaprevir, pibrentasvir  + sofosbuvir + ribavirin (G/P+SOF+RBV) for the rescue treatment of patients with chronic hepatitis C who failed to voxilaprevir, velpatasvir, sofosbuvir (VOX/VEL/SOF) as retreatment. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 19, 2021 Category: Gastroenterology Authors: Julia Dietz, Christoph Sarrazin Tags: Letter to the Editor Source Type: research

FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Cholangiocarcinoma (CCA) is a neoplasia of the biliary tract driven by genetic, epigenetic and transcriptional mechanisms. Here, we investigated the role of the transcription factor FOSL1, as well as its downstream transcriptional effectors, in the development and progression of CCA. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 19, 2021 Category: Gastroenterology Authors: Adri án Vallejo, Oihane Erice, Rodrigo Entrialgo-Cadierno, Iker Feliu, Elizabeth Guruceaga, Maria J. Perugorria, Paula Olaizola, Alexandra Muggli, Irati Macaya, Michael O’Dell, Borja Ruiz-Fernandez de Cordoba, Sergio Ortiz-Espinosa, Aram F. Hezel, Iman Source Type: research

Reply to: “Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice”
We thank Dr. Xu et al. for their insightful letter1 and take advantage of this reply to clarify important aspects of our article,2 in which we employed a well-established mouse model of liver ischemia-reperfusion injury (IRI) to show that activation of YAP attenuated oxidative stress and innate immune responses in liver IRI. As activation of YAP prevented hepatocellular damage in liver IRI, it further mitigated IR-mediated liver fibrosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 19, 2021 Category: Gastroenterology Authors: Yuan Liu, Ning Xu, Haofeng Ji Tags: Letter to the Editor Source Type: research

Reply to “glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings”
We thank Dr. Martin and colleagues for their interest in our study and for presenting additional data on the usage of glecaprevir, pibrentasvir + sofosbuvir + ribavirin (G/P+SOF+RBV) for the rescue treatment of patients with chronic hepatitis C who failed to voxilaprevir, velpatasvir, sofosbuvir (VOX/VEL/SOF) as retreatment. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 19, 2021 Category: Gastroenterology Authors: Julia Dietz, Christoph Sarrazin Tags: Letter to the Editor Source Type: research

Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis
Despite a marked reduction in new cases of liver cirrhosis caused by hepatitis C virus (HCV) infection, over 500,000 new cirrhosis cases in this category were estimated globally in 2019. This contribution quantifies the relationship between alcohol use and the progression of liver disease in people with HCV infections. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 19, 2021 Category: Gastroenterology Authors: Laura Llamosas-Falc ón, Kevin D. Shield, Maya Gelovany, Omer S.M. Hasan, Jakob Manthey, Maristela Monteiro, Nick Walsh, Jürgen Rehm Source Type: research

Falls are common, morbid, and predictable in patients with cirrhosis
Falls are a devastating complication of cirrhosis. The risk of falls in contemporary patients without HE is unclear. Further, bedside tools for predicting falls are lacking (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 19, 2021 Category: Gastroenterology Authors: Elliot B. Tapper, Samantha Nikirk, Neehar Parikh, Lilli Zhao Source Type: research

Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis
Obesity often leads to nonalcoholic fatty liver disease (NAFLD), which can progress from simple steatosis (nonalcoholic fatty liver (NAFL)) to nonalcoholic steatohepatitis (NASH). The accumulation of certain lipid subtypes is linked with worsening metabolic and liver disease, however, specific changes during progression from No-NAFL to NAFL then NASH are unresolved. Here, we characterise the liver, adipose tissue and plasma lipidome of worsening NAFLD in obesity, and evaluate the utility of plasma lipids as biomarkers of NAFLD. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 19, 2021 Category: Gastroenterology Authors: Geraldine J. Ooi, Peter J. Meikle, Kevin Huynh, Arul Earnest, Stuart K. Roberts, William Kemp, Benjamin L. Parker, Wendy Brown, Paul Burton, Matthew J. Watt Source Type: research

Decrease in viral hepatitis diagnoses during the covid-19 pandemic in the netherlands
Study concept and design, data acquisition and analysis, critical revision of manuscript for important intellectual content and approval of final version: all authors (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 19, 2021 Category: Gastroenterology Authors: Milan J. Sonneveld, Irene K. Veldhuijzen, Thijs van de Laar, Eline L.M. Op de Coul, Adriaan J. van der Meer Tags: Letter to the Editor Source Type: research

Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis
Beneficial effect of bezafibrate (BZF) on symptoms and biochemical features of primary biliary cholangitis (PBC) with incomplete response to ursodeoxycholic acid (UDCA) has been reported but long-term efficacy on survival remains unknown. In Japan, BZF has been used as a de facto second-line therapy for PBC since 2000. Herein, we compared the survival rates between patients treated with and those without BZF in a large nationwide Japanese PBC cohort. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 18, 2021 Category: Gastroenterology Authors: Atsushi Tanaka, Junko Hirohara, Toshiaki Nakano, Kosuke Matsumoto, Olivier Chazouill ères, Hajime Takikawa, Bettina E. Hansen, Fabrice Carrat, Christophe Corpechot Source Type: research

Editorial Board
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Source Type: research

Discover key sessions at the International Liver Congress ™ 2021
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Source Type: research

Submit your abstract for the Digital NAFLD Summit 2021
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Source Type: research

Join the EASL Community & enjoy reduced fees to all EASL events
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Source Type: research

Visit EASL Campus & discover 4,100 + resources on hepatology & liver-related research
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Source Type: research

Contents
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Source Type: research

JHEP at a glance (May 2021)
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Source Type: research

From the Editor ’s Desk...
Hepatocellular carcinoma (HCC) tumours activate telomerase early during hepatocarcinogenesis. Ningarhari et  al. have thoroughly studied the relevance of telomere length. They showed that TERT promoter mutations are frequent in HCC tumours arising in livers with short telomeres but not in those with long telomeres. In HCC tumours, long telomeres indicated very aggressive behaviour and were associated wit h the G3 transcriptomic subclass. Silencing TERT with antisense oligonucleotide was efficient in vitro, indicating a TERT oncogenic addiction, and was also effective against HCC in a xenograft mouse model, openin...
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli Tags: From the Editor's Desk Source Type: research

Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis
Primary sclerosing cholangitis (PSC) is characterized by chronic inflammation and progressive fibrosis of the biliary tree. The bile acid receptor TGR5 is found on biliary epithelial cells (BECs), where it promotes secretion, proliferation and tight junction integrity. Thus, we speculated that changes in TGR5-expression in BECs may contribute to PSC pathogenesis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Authors: Maria Reich, Lina Spomer, Caroline Klindt, Katharina Fuchs, Jan Stindt, Kathleen Deutschmann, Johanna H öhne, Evaggelia Liaskou, Johannes R. Hov, Tom H. Karlsen, Ulrich Beuers, Joanne Verheij, Sofia Ferreira-Gonzalez, Gideon Hirschfield, Stuart J. Forbes Source Type: research

Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates compared to standard weight-based dosing of thiopurine therapy
Patients with autoimmune hepatitis (AIH) usually receive maintenance therapy with thiopurines, such as azathioprine (AZA) or mercaptopurine (MP). Genetic polymorphisms in AZA metabolism can lead to variations in thioguanine nucleotide (TGN) and 6-methylmercaptopurine (MMP), both of which can cause adverse drug reactions (ADR). In inflammatory bowel disease (IBD), a therapeutic TGN range (225-450 pmol/8x108 erythrocytes) has been identified to optimise effectiveness. We evaluated the benefits of a personalised medicine approach to thiopurine dosing, in comparison to standard weight-based dosing. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 16, 2021 Category: Gastroenterology Authors: Lena S. Candels, Mussarat N. Rahim, Sital Shah, Michael A. Heneghan Source Type: research

Reply to: “Achieving an effective pressure reduction after TIPS: The need for a new target”
I thank Drs Wang et  al.1 for their kind comments on my paper. As I emphasized, hemodynamic targets for TIPS are largely based on studies from the pre-covered stent era, when TIPS dysfunction was extremely common.2 At that time, we showed that reducing the portal pressure gradient (PPG, the difference between portal v ein and hepatic vein pressure) to values below 12 mmHg was necessary to prevent rebleeding or ascites, but that reductions below 10 mmHg were associated with an increased risk of encephalopathy. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 15, 2021 Category: Gastroenterology Authors: Jaume Bosch Tags: Letter to the Editor Source Type: research

Reply to: “A step forward to predict the risk of post-hepatectomy portal hypertension”
We would like to thank Wang et  al. for their careful reading and constructive comments1 on our manuscript.2 We would like to provide some clarifications and explanations regarding the limitations formulated. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 15, 2021 Category: Gastroenterology Authors: Nicolas Golse, Eric Vibert, Irene E. Vignon-Clementel Tags: Letter to the Editor Source Type: research

Effective portal-pressure gradient reduction after small diameter TIPS
I thank Drs Wang et al.1 for their kind comments on my paper. As I emphasized, hemodynamic targets for TIPS are largely based on studies from the pre-covered stent era, when TIPS dysfunction was extremely common.2 At that time, we showed that reducing the portal pressure gradient (PPG, the difference between portal vein and hepatic vein pressure) to values below 12 mmHg was necessary for preventing rebleeding or ascites, but that reductions below 10 mmHg were associated with an increased risk of encephalopathy. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 15, 2021 Category: Gastroenterology Authors: Jaume Bosch Tags: Letter to the Editor Source Type: research

Comments on: “A step forward to predict the risk of post-hepatectomy portal hypertension”
We would like to thank Wang et al. for their careful reading and constructive comments1 to our manuscript on assessing the risk of post-hepatectomy portal hypertension using a hemodynamics digital twin.2 We would like to provide some clarifications and explanations to the limitations formulated. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 15, 2021 Category: Gastroenterology Authors: Nicolas Golse, Eric Vibert, Irene E. Vignon-Clementel Tags: Letter to the Editor Source Type: research

Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity
To evaluate the association between muscle mass and fatty infiltration and biopsy-assessed NAFLD in patients with obesity. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 14, 2021 Category: Gastroenterology Authors: Maxime Nachit, Wilhelmus J. Kwanten, Jean-Paul Thissen, Bart Op De Beeck, Luc Van Gaal, Luisa Vonghia, An Verrijken, Ann Driessen, Yves Horsmans, Sven Francque, Isabelle A. Leclercq Tags: Research Article Source Type: research

Reply to: “Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients”
We read with great interest the letter by G. J. Webb et  al.1 regarding our recent nationwide study promoted by the Spanish Society of Liver Transplantation (SETH), which evaluated the incidence and outcomes of coronavirus disease 2019 (COVID-19) in liver transplant (LT) patients.2 The authors merged the SETH data with their own international cohort (CO VID-Hep/SECURE-Cirrhosis)3 resulting in 258 LT patients with COVID-19. The combined data analysis allowed them to highlight the importance of age and comorbidities as key factors influencing outcomes. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 13, 2021 Category: Gastroenterology Authors: Manuel Rodr íguez-Perálvarez, Jordi Colmenero, Magdalena Salcedo, Spanish Society of Liver Transplantation (SETH) Tags: Letter to the Editor Source Type: research

Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?
FB: Patient care, writing of the manuscript, and revision of the final version of the manuscript. SAD: Pathology reading, and revision of the final version of the manuscript. MD: Patient care, and revision of the final version of the manuscript. DMF: Patient care, and revision of the final version of the manuscript. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 13, 2021 Category: Gastroenterology Authors: Fernando Bril, Sameer Al Diffalha, Mark Dean, David M. Fettig Tags: Letter to the Editor Source Type: research